Syros Pharmaceuticals, Inc. (SYRS)

NASDAQ: SYRS · IEX Real-Time Price · USD
3.83
-0.17 (-4.25%)
At close: Dec 5, 2022 4:00 PM
3.81
-0.02 (-0.52%)
After-hours: Dec 5, 2022 5:11 PM EST
-4.25%
Market Cap 80.57M
Revenue (ttm) 23.44M
Net Income (ttm) -113.69M
Shares Out 9.42M
EPS (ttm) -1.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date Sep 19, 2022
Volume 96,293
Open 3.99
Previous Close 4
Day's Range 3.82 - 4.01
52-Week Range 3.52 - 43.3
Beta 1.48
Analysts Buy
Price Target 146.47 (+3,724.3%)
Earnings Date Nov 14, 2022

About SYRS

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute... [Read more]

Industry Biotechnology
IPO Date Jun 30, 2016
CEO Nancy Simonian
Employees 124
Stock Exchange NASDAQ
Ticker Symbol SYRS
Full Company Profile

Financial Performance

In 2021, SYRS's revenue was $23.49 million, an increase of 55.62% compared to the previous year's $15.09 million. Losses were -$86.56 million, 3.00% more than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for SYRS stock is "Buy." The 12-month stock price forecast is 146.47, which is an increase of 3,724.28% from the latest price.

Price Target
$146.47
(3,724.28% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloi...

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a virtual event...

13 hours ago - Business Wire

Syros to Participate at Piper Sandler 34th Annual Healthcare Conference

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer,...

1 week ago - Business Wire

Syros Pharmaceuticals, Inc. (SYRS) Reports Q3 Loss, Misses Revenue Estimates

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 38.36% and 21.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

3 weeks ago - Zacks Investment Research

Syros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ...

3 weeks ago - Business Wire

GLSI, APRN: The Top 5 Short Squeeze Stocks to Watch This Week

Source: g0d4ather / Shutterstock.com Investors are still interested in short squeeze stocks and we've got them covered with the ones to watch this week! Fintel is offering up a list of the short squeeze...

Other symbols: APRNGLSIPETZSURG
2 months ago - InvestorPlace

Syros Pharmaceuticals, Inc. (SYRS) Upgraded to Buy: What Does It Mean for the Stock?

Syros Pharmaceuticals, Inc. (SYRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago - Zacks Investment Research

Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the closing of its merger wit...

2 months ago - Business Wire

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syros Pharmaceuticals, Inc. for Potential Breaches of Fid...

NEW YORK , Sept. 15, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ...

2 months ago - PRNewsWire

Syros (SYRS) Up on FDA's Orphan Tag for Pancreatic Cancer Drug

Syros Pharmaceuticals (SYRS) receives Orphan Drug designation from the FDA for its pipeline candidate AY-5609 being developed for treating metastatic pancreatic cancer. Stock up.

2 months ago - Zacks Investment Research

Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the U.S. Food and Drug A...

2 months ago - Business Wire

Syros to Present at H.C. Wainwright 24th Annual Global Investment Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, N...

2 months ago - Business Wire

TYME TECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Ade...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of TYME Technologies,...

3 months ago - Business Wire

Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Tops Revenue Estimates

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -28.57% and 34.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Syros Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter en...

3 months ago - Business Wire

Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for th...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the European Medicines Agency ...

4 months ago - Business Wire

Syros to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference...

4 months ago - Business Wire

Syros Pharmaceuticals, Inc. (SYRS) Moves to Strong Buy: Rationale Behind the Upgrade

Syros Pharmaceuticals, Inc. (SYRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

4 months ago - Zacks Investment Research

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Tyme Technologies, Inc. Merger

Wilmington, Delaware--(Newsfile Corp. - July 6, 2022) - Rigrodsky Law, P.A. is investigating Tyme Technologies, Inc. ("Tyme") (NASDAQ: TYME) regarding possible breaches of fiduciary duties and other vio...

4 months ago - Newsfile Corp

SHAREHOLDER ALERT: Weiss Law Investigates Syros Pharmaceuticals, Inc.

NEW YORK , July 5, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Syros Pharmaceuticals, Inc. ("Syros" or th...

5 months ago - PRNewsWire

TYME Technologies Shares Surge On Merger Agreement With Syros Pharma

Syros Pharmaceuticals Inc (NASDAQ: SYRS) has agreed to acquire TYME Technologies Inc (NASDAQ: TYME), including its pipeline assets and net cash, after accounting for wind-down and transaction expenses c...

5 months ago - Benzinga

Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement

CAMBRIDGE, Mass. & BEDMINSTER, N.J.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and TYME Technologies, Inc. (NAS...

5 months ago - Business Wire

Syros to Present at JMP Securities Life Sciences Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, N...

5 months ago - Business Wire